None
Conditions
Interventions
Experimental group:Subjects in this group received an initial intravenous injection of a combination of "midazolam and sufentanil," with midazolam administered at a dose of 0.03-0.05 mg/kg and sufenta
Control group:Participants in this group underwent standard surgical procedures for respiratory training. Once they were able to control their breathing as instructed, percutaneous lung puncture was c
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 and < 80 years, with no gender restrictions; 2. Patients scheduled for percutaneous puncture intervention in the lungs, encompassing procedures such as percutaneous biopsy and tumor ablation; 3. Patients willing to undergo mild to moderate sedation; 4. Patients in good general condition, classified as American Society of Anesthesiologists (ASA) Health Status Grades I or II; Patients with ASA Grades III or IV in a stable condition should be closely monitored during the procedure; 5.The patient fully comprehends the benefits and risks associated with this trial, is willing to participate, and has signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients presenting with skin redness, swelling, damage, symptoms of skin diseases, or an inability to affix markers due to skin conditions at the puncture site, as well as those with acute suppurative infections in the pleural cavity; 2.Patients with a platelet count below 50 × 10^9/L, severe bleeding tendencies, or coagulation disorders that cannot be promptly corrected (prothrombin time exceeding 18s, prothrombin activity below 40%), or those who have discontinued anticoagulant and/or antiplatelet therapy no more than 5-7 days prior to ablation, and whose last use of bevacizumab was within the past month; 3.Patients with severe systemic infections and high fever (>38.5?); 4. Patients with pneumothorax risk due to other conditions such as pulmonary bullae or pulmonary cysts along the intended puncture path; 5. Patients with poorly controlled pleural effusion; 6. Critically ill patients with severe dysfunction of the heart, liver, lungs, or kidneys; 7. Patients unable to cooperate or tolerate the puncture procedure; 8. Women who are pregnant or breastfeeding, as well as individuals who cannot be exposed to intraoperative radiation; 9. Patients classified as ASA grade V; 10. Applicable only to the mild to moderate sedation group: patients without an accompanying person or guardian; 11. Patients with allergies to sedatives/anesthetics or those at extremely high anesthesia risk; 12.Patients who have participated or are currently participating in another clinical trial within the 28 days prior to screening; 13. Patients deemed by researchers to have poor compliance or other reasons unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Puncture accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Puncture accuracy rate;Puncture time;Number of punctures;Displacement of pulmonary nodules;Puncture difficulty VAS score; | — |
Countries
China
Contacts
Public ContactLin Xinqing
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed